American Society of Hematology. (2019).
FDA Approves Acalabrutinib for CLL and SLL.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-acalabrutinib-for-cll-and-sll.
American Society of Hematology.
"FDA Approves Acalabrutinib for CLL and SLL." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-acalabrutinib-for-cll-and-sll
(label-accessed March 29, 2023).
"American Society of Hematology."
FDA Approves Acalabrutinib for CLL and SLL, 29 Mar. 2023 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-acalabrutinib-for-cll-and-sll.
